- Min.Order :1 Gram
- Purity: 95%
Keywords
4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-me Enzalutamide androgen receptor antagonist
Quick Details
- Appearance:white powder
- Application:Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-re
- PackAge:
- ProductionCapacity:|Metric Ton|Day
- Storage:
- Transportation:
Superiority:
HIgh Quality
Details:
Enzalutamide (marketed as Xtandi formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation fthe treatment of metastatic castration-resistant prostate cancer.[1] Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.[2]Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth.[3][4] In August of 2012, theU.S. Food Drug Administration approved enzalutamide fthe treatment of castration-resistant prostate cancer.
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View